Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system

Blood

Volumn 118, Issue 6, 2011, Pages 1685-1692

  Luft, Thomas ^a,b   Dietrich, Sascha ^a,b   Falk, Christine ^c   Conzelmann, Michael ^a   Hess, Michael ^a,b   Benner, Axel ^b   Neumann, Frank ^d   Isermann, Berend ^a   Hegenbart, Ute ^a   Ho, Anthony D ^a   Dreger, Peter ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d Moor Court Farm   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; CYCLOSPORIN A; CYTOKERATIN 18; FAS LIGAND; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THROMBOMODULIN; VASCULOTROPIN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CELL ACTIVITY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRIORITY JOURNAL; STEROID THERAPY; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

EID: 80051604321     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-334821     Document Type: Article

References (32)

1. Alousi AM, Weisdorf DJ, Logan BR, et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood. 2009;114(3):511-517.
2. Van Lint MT, Milone G, Leotta S, et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood. 2006;107(10):4177-4181. (Pubitemid 43726830)
3. Deeg HJ. How I treat refractory acute GVHD. Blood. 2007;109(10):4119- 4126. (Pubitemid 46743372)
4. MacMillan ML, Weisdorf DJ, Brunstein CG, et al. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood. 2009;113(11):2410-2415.
5. Schmitt T, Luft T, Hegenbart U, Tran TH, Ho AD, Dreger P. Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective singlecenter analysis. Bone Marrow Transplant. 2011;46(4):580-585.
6. Ferrara JL, Levine JE, Reddy P, Holler E. Graftversus- host disease. Lancet. 2009;373(9674):1550-1561.
7. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295-304.
8. Luft T, Conzelmann M, Benner A, et al. Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graftversus-host disease. Blood. 2007;110(13):4535-4542. (Pubitemid 351377821)
9. Biedermann BC, Sahner S, Gregor M, et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet. 2002;359(9323):2078-2083. (Pubitemid 34680972)
10. Dumler JS, Beschorner WE, Farmer ER, Di Gennaro KA, Saral R, Santos GW. Endothelial- cell injury in cutaneous acute graft-versus-host disease. Am J Pathol. 1989;135(6):1097-1103. (Pubitemid 20026529)
11. Holler E, Kolb HJ, Hiller E, et al. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood. 1989;73(7):2018-2024. (Pubitemid 19145140)
12. Biedermann BC, Tsakiris DA, Gregor M, Pober JS, Gratwohl A. Combining altered levels of effector transcripts in circulating T cells with a marker of endothelial injury is specific for active graft-versus-host disease. Bone Marrow Transplant. 2003;32(11):1077-1084. (Pubitemid 37540738)
13. Hanly AM, Hayanga A, Winter DC, Bouchier-Hayes DJ. Thrombomodulin: tumour biology and prognostic implications. Eur J Surg Oncol. 2005;31(3):217-220. (Pubitemid 40361508)
14. Nurnberger W, Michelmann I, Burdach S, Gobel U. Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant- related complications. Ann Hematol. 1998;76(2):61-65. (Pubitemid 28118725)
15. Testa S, Manna A, Porcellini A, et al. Increased plasma level of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation. Bone Marrow Transplant. 1996;18(2):383-388. (Pubitemid 26283690)
16. Thomas M, Augustin HG. The role of the Angiopoietins in vascular morphogenesis. Angiogenesis. 2009;12(2):125-137.
17. Fiedler U, Reiss Y, Scharpfenecker M, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med. 2006;12(2):235-239. (Pubitemid 43214752)
18. Ricciuto DR, Dos Santos CC, Hawkes M, et al. Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis. Crit Care Med. 2011;39(4):702-710.
19. Kumpers P, David S, Haubitz M, et al. The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus. Ann Rheum Dis. 2009;68(10):1638-1643.
20. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A. 2002;99(17):11205-11210. (Pubitemid 34920903)
21. Oshima Y, Oshima S, Nambu H, et al. Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitive. FASEB J. 2005;19(8):963-965. (Pubitemid 40827718)
22. Min CK, Kim SY, Lee MJ, et al. Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;38(2):149-156.
23. Sullivan K. Graft-versus-host-disease. In: ED T, ed. Hematopoietic Cell Transplantation. Boston, MA: Blackwell Science; 1999:515-536.
24. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956. (Pubitemid 41754712)
25. Gratwohl A, Stern M, Brand R, et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer. 2009;115(20):4715-4726.
26. Leisenring WM, Martin PJ, Petersdorf EW, et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood. 2006;108(2):749-755. (Pubitemid 44061380)
27. Levine JE, Logan B, Wu J, et al. Graft-versus-host disease treatment: predictors of survival. Biol Blood Marrow Transplant. 2010;16(12):1693-1699.
28. Wagner AH, Gebauer M, Pollok-Kopp B, Hecker M. Cytokine-inducible CD40 expression in human endothelial cells is mediated by interferon regulatory factor-1. Blood. 2002;99(2):520-525. (Pubitemid 34533087)
29. Palomo M, Diaz-Ricart M, Carbo C, et al. The release of soluble factors contributing to endothelial activation and damage after hematopoietic stem cell transplantation is not limited to the allogeneic setting and involves several pathogenic mechanisms. Biol Blood Marrow Transplant. 2009;15(5):537-546.
30. Weinberg A, Zhang L, Hayward AR. Alloreactive cytotoxic CD4+ responses elicited by cytomegalovirus- infected endothelial cells: role of MHC class I antigens. Viral Immunol. 2000;13(1):37-47. (Pubitemid 30151779)
31. Isermann B, Sood R, Pawlinski R, et al. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med. 2003;9(3):331-337. (Pubitemid 36362789)
32. Penack O, Socie G, van den Brink MR. The importance of neovascularization and its inhibition for allogeneic hematopoietic stem cell transplantation. Blood. 2011;117(16):4181-4189.